Immunization

NFID Announces 2024 Recipients of Prestigious Awards

Retrieved on: 
Tuesday, April 9, 2024
RN, Maxwell Finland Award, COVAX, Health equity, HIV, Biomedical Research, Health, Patient, Epidemic, Infection, Rockefeller Foundation, Vaccine, Ageing, AIDS, International, Education, Policy, Master of Science, Woman, Gavi, World Health Organization, Immunization, Safety, Disease, Global health, Public, Research, Death, Mentorship, NFID, MPH, National Academy of Medicine, CPNP, COVID-19, IAVI, National academy, Developed country

BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work. The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:

Key Points: 
  • BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work.
  • The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:
    Seth F. Berkley, MD, of the Pandemic Center of Brown University, will receive the 2024 Jimmy and Rosalynn Carter Humanitarian Award in recognition of his work as an innovative entrepreneur, a pioneer in global health, and a champion of equitable access to vaccines.
  • The awards will be presented at the 2024 NFID Awards Gala and Silent Auction, a black-tie fundraising event scheduled for September 19, 2024, in Washington, DC.
  • All contributions support the NFID mission to educate the public and healthcare professionals on the prevention and treatment of infectious diseases.

Viral Vector and Plasmid DNA Technologies and Global Market Analysis - A USD 7.1 Billion Market by 2028, Expansion of Biotechnological Applications Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Infectious Diseases, Genetics, Science, AAV, Transfection, QC, HSV, Acute lymphoblastic leukemia, Growth, Prevalence, Cell, Incidence, ALL, Tissue, DNA, Mortality, Virus, Cancer, Human, Infection, World Health Organization, Neoplasm, Immunization, Safety, WHO, Therapy, Inosine pranobex, USD, DSM-IV codes, Tisagenlecleucel, Vaccine

The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.

Key Points: 
  • The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.
  • However, regulatory challenges, vector characterization, and QC testing, and manufacturing challenges have restrained growth in the global viral vector and plasmid DNA technologies market.
  • The global viral vector and plasmid DNA technologies market is segmented based on the product, application, and end-user.
  • Based on the product, the global viral vector and plasmid DNA technologies market further is analyzed into plasmid DNA and viral vectors.

ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis

Retrieved on: 
Tuesday, March 26, 2024
Intelligence, AP, Sanofi, Vaccine, NLP, Growth, Natural language processing, Immunization, Interview, Vaccination

This recent comprehensive study analyzes global volumes and utilization trends for aP combination vaccines, including hexavalent and pentavalent vaccines, and confirms Sanofi's leadership in the global pediatric combination vaccine market.

Key Points: 
  • This recent comprehensive study analyzes global volumes and utilization trends for aP combination vaccines, including hexavalent and pentavalent vaccines, and confirms Sanofi's leadership in the global pediatric combination vaccine market.
  • The study reveals a notable rebound in immunization rates, with DTP3 coverage rising to 84% in 2022, and delves into global trends in the utilization of aP-based hexavalent and pentavalent combination vaccines, highlighting significant market dynamics and leadership.
  • Geographically, Europe is noted for its significant share of the aP-based combination vaccines market, especially in the hexavalent and pentavalent categories.
  • This regional analysis, along with a detailed breakdown of vaccine usage in top countries, offers a clear view of global vaccination strategies and their impact.

ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis

Retrieved on: 
Tuesday, March 26, 2024
Intelligence, AP, Sanofi, Vaccine, NLP, Growth, Natural language processing, Immunization, Interview, Vaccination

This recent comprehensive study analyzes global volumes and utilization trends for aP combination vaccines, including hexavalent and pentavalent vaccines, and confirms Sanofi's leadership in the global pediatric combination vaccine market.

Key Points: 
  • This recent comprehensive study analyzes global volumes and utilization trends for aP combination vaccines, including hexavalent and pentavalent vaccines, and confirms Sanofi's leadership in the global pediatric combination vaccine market.
  • The study reveals a notable rebound in immunization rates, with DTP3 coverage rising to 84% in 2022, and delves into global trends in the utilization of aP-based hexavalent and pentavalent combination vaccines, highlighting significant market dynamics and leadership.
  • Geographically, Europe is noted for its significant share of the aP-based combination vaccines market, especially in the hexavalent and pentavalent categories.
  • This regional analysis, along with a detailed breakdown of vaccine usage in top countries, offers a clear view of global vaccination strategies and their impact.

Oracle Delivers Foundation for More Intelligent Healthcare

Retrieved on: 
Tuesday, March 12, 2024
Cloud, RN, Health, ROI, Government, Risk management, Intelligence, Diabetes, Patient, Oracle Cloud, Public, DNP, Health information management, OCI, AI, IDC, Overalls, HIMSS, Address, Immunization, Oracle, Breast cancer, CCM, EHR, Medicare, Update, Medical device

AUSTIN, Texas, March 12, 2024 /PRNewswire/ -- Oracle today announced significant enhancements to Oracle Health Data Intelligence, including a new generative AI service to help increase care management efficiency. Oracle Health Data Intelligence, formerly HealtheIntent, is a modular suite of cloud applications, services, and analytics. The suite enables a broad range of healthcare and government stakeholders to use data from across the healthcare ecosystem to help advance patient health, improve care delivery, and drive operational efficiency. Additional new capabilities include system performance improvements, pre-built clinical quality analytics, and automated alerts that can help increase reimbursements and enhance care.

Key Points: 
  • Oracle Health Data Intelligence, formerly HealtheIntent, is a modular suite of cloud applications, services, and analytics.
  • Powered by Oracle Cloud Infrastructure (OCI), Oracle Health Data Intelligence gives customers access to the same mission-critical security, performance, reliability, and other cloud capabilities that Fortune 100 customers in highly regulated industries rely on today.
  • To see Oracle Health in action, please visit us at HIMSS in Orlando March 11 - 15 at booth #2761.
  • Learn how Oracle Health is building an open healthcare platform with intelligent tools for data-driven, human-centric health experiences to connect consumers, providers, payers, public health, and life sciences.

World Vaccine Congress Draws Leaders from Government, Science and Industry

Retrieved on: 
Monday, March 11, 2024
Convention center, Bee, Washington Convention Center, Congress, Walter, Global health, Mayo Clinic, Food and Drug Administration, Cancer, International, Science Advisory Board, World Health Organization, Immunization, Vaccination, Bangladesh Technical Education Board, Vaccine, Food, Pharmaceutical industry

WASHINGTON, March 11, 2024 /PRNewswire/ -- The world's top experts and policymakers, including government leaders, renown researchers and company executives driving vaccine development, will gather to discuss the latest progress in vaccines — from efforts to inoculate bees to a discussion of pathogens that could cause the next pandemic — at the World Vaccine Congress April 1-4.

Key Points: 
  • "We have assembled the world's foremost experts and policymakers in the field of vaccination for the 2024 World Vaccine Congress," said Dr. Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and a member of the Science Advisory Board.
  • "This event represents an unparalleled opportunity for collaboration and innovation and promises to drive meaningful progress in global health.
  • It is a unique and massive forum for discovery and access to leaders across the field."
  • In-depth sessions also cover vaccine supply and logistics, veterinary vaccines, emerging diseases, and vaccine delivery.

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Retrieved on: 
Monday, March 4, 2024
SAN, Immunization, PCV, Serology, Life, Vaccine, Safety, Meningitis, Genetically modified bacteria, IPD, Tolerability, Infant, Disease, Streptococcus pneumoniae, Fungal infection

SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in its Phase 2 study evaluating VAX-24, a broad-spectrum, carrier-sparing 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy infants. Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.

Key Points: 
  • Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.
  • “Completing enrollment of the VAX-24 study with more than 800 healthy infants demonstrates yet another significant milestone in the development of our VAX-24 and VAX-31 PCV candidates,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
  • “We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market or in U.S. clinics today.
  • “Given the significant burden of disease in young children, there remains a need for broader-spectrum vaccines like VAX-24 and VAX-31, our next-generation 31-valent PCV candidate, that are designed to provide greater protection than the current standard-of-care.”

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024
Licensure, Investment, Growth, Exercise, Tolerability, Immunization, Host, Trial of the century, Ageing, PCV20, PCV, P-value, Safety, BLA, Success, Phase 10, Genetically modified bacteria, Net, G&A, CMC, SAN, Research and development, ID, OPA, Conference, The Lancet, Biologics license application, Breakthrough therapy, Advisory Committee, PCV15, POC, FDA, End, Food, Breakthrough, Element, Fireside chats, Administration, IPD

-- Significant Progress in Establishing Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, Including Expanded Collaboration with Lonza --

Key Points: 
  • ET / 1:30 p.m. PT --
    SAN CARLOS, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Additionally, as part of ongoing Chemistry, Manufacturing and Controls (CMC)-focused discussions, Vaxcyte received encouraging input from the FDA regarding the VAX-24 adult licensure requirements.
  • The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied.
  • Vaxcyte will host a conference call and webcast to discuss this announcement today, February 27, 2024, at 4:30 p.m.

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

Retrieved on: 
Wednesday, February 21, 2024
EBS, Immunization, Emergent BioSolutions, FDA, Growth, U.S. FDA, Life, Post-exposure prophylaxis, Public, Vaccine

Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024.

Key Points: 
  • Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024.
  • "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent,” said Zsolt Harsanyi, Ph.D., chairman of the Board of Directors.
  • “He is a recognized industry leader with unparalleled experience in all facets of the pharmaceutical and healthcare industry.
  • “I am confident that these important products provide for a bright future ahead as Emergent continues to lead in public health preparedness.

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

Retrieved on: 
Wednesday, February 21, 2024
Immunization, G protein-coupled receptor, Drug discovery, ADC, Antibody, Eurosport 1, Protein, Cancer, Vaccine

ROCHESTER, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer through the inhibition of SEMA4D, announces that it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug transmembrane protein targets.

Key Points: 
  • ActivMAb’s new “Antigen Virus” application is a powerful complement to drug discovery strategies targeting complex protein targets including ion channels and G-protein coupled receptors (GPCRs) such as chemokine receptors.
  • We believe that this is a much more highly purified presentation and efficient selection technology than the complex natural membrane fragments that have been termed virus-like particles.
  • “We have recently publicized success in selecting high value antibodies against challenging multi-pass membrane targets.
  • We are excited to be able to capitalize on what we believe is recognition of the unique capabilities of our drug discovery technology.